

United States Patent and Trademark Office



APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/830,176	04/23/2001	Ron Yacov	13257-00040	2969
34055	7590 10/18/2002			
PERKINS CO			ЕХАМП	NER
POST OFFICE SEATTLE, W.	A 98111-1208		WOITACH,	JOSEPH T
			ART UNIT	PAPER NUMBER
			1632	
			DATE MAILED: 10/18/2002	12

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE		FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/830,176	05/21/01	Yacov et al.		13257-00040

EXA	MINER
Joseph Woitach	
ART UNIT	PAPER NUMBER
1632	12

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Specifically, the CRF filed July 30, 2001, paper number 4, was entered, however polynucleotide sequences are present in the specification but they are not identified with SEQ ID NOs (see page 19, line 14 for example). For proper sequence compliance each sequence present in the disclosure must be identified by a SEQ ID NO and be present in the sequence listing. Appropriate correction is required.

APPLICANT IS GIVEN **30 days** FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. **In no case may an applicant extend the period for response beyond the six month statutory period**. Applicant is requested to return a copy of the attached Notice to Comply with the response. Note that a reply to a notice to comply with the sequence rules should **not** be sent to the 20231 zip code address for the United States Patent and Trademark Office.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph Woitach whose telephone number is (703)305-3732.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah Reynolds, can be reached at (703)305-4051.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist Pauline Farrier whose telephone number is (703)305-3550.

Joseph T. Woitach

DEBORAH CROUCH PRIMARY EXAMINER GROUP 1900/630

Deboral Cond

Appl	on No.:	09/830,176	
			•

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

This application clearly fails to comply with the requirements of attention is directed to the final rulemaking notice published at OG 29 (May 15, 1990). If the effective filing date is on or after notice published at 63 FR 29620 (June 1, 1998) and 1211 OC.	at 55 FR 18230 (May 1, 1990), and 1114 er July 1, 1998, see the final rulemaking G 82 (June 23, 1998).
	sclosure on paper copy, a "Sequence
2. This application does not contain, as a separate part of the dis Listing" as required by 37 C.F.R. 1.821(c).	•
3. A copy of the "Sequence Listing" in computer readable form h 37 C.F.R. 1.821(e).	nas not been submitted as required by
4. A copy of the "Sequence Listing" in computer readable form h content of the computer readable form does not comply with t and/or 1.823, as indicated on the attached copy of the market	the requirements of 37 C.F.R. 1.822
5. The computer readable form that has been filed with this appl and/or unreadable as indicated on the attached CRF Diskette computer readable form must be submitted as required by 37	Problem Report. A Substitute
6. The paper copy of the "Sequence Listing" is not the same as to "Sequence Listing" as required by 37 C.F.R. 1.821(e).	the computer readable from of the
7. Other:	
Applicant Must Provide:	
An initial or <u>substitute</u> computer readable form (CRF) copy of the	e "Sequence Listing".
An initial or <u>substitute</u> paper copy of the "Sequence Listing", as vinto the specification.	well as an amendment directing its entr
A statement that the content of the paper and computer readable applicable, include no new matter, as required by 37 C.F.R. 1.82 1.825(b) or 1.825(d).	e copies are the same and, where 21(e) or 1.821(f) or 1.821(g) or
For questions regarding compliance to these requiremen	its, please contact:
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 Patentln Software Program Support Technical Assistance	287-0200 206-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY